| Unique ID issued by UMIN | UMIN000061387 |
|---|---|
| Receipt number | R000070237 |
| Scientific Title | A Prospective Interventional Study to Evaluate Changes in Pulmonary Function Following Carbon-Ion Radiotherapy for Lung Tumors |
| Date of disclosure of the study information | 2026/04/27 |
| Last modified on | 2026/04/27 14:04:01 |
A prospective interventional study evaluating changes in pulmonary function following carbon-ion radiotherapy for lung tumors
Pulmonary function after carbon-ion radiotherapy for lung tumors
A Prospective Interventional Study to Evaluate Changes in Pulmonary Function Following Carbon-Ion Radiotherapy for Lung Tumors
Prospective study of pulmonary function afafte carbon-ion radiotherapy for lung tumors
| Japan |
Patients receiving carbon-ion radiotherapy for primary lung cancer or metastatic lung tumors
| Radiology |
Malignancy
NO
To prospectively evaluate pulmonary function in patients with primary lung cancer or metastatic lung tumors treated with carbon-ion radiotherapy, and to analyze the impact of the treatment on respiratory function and its association with follow-up data, including post-treatment adverse events.
Safety
Not applicable
Absolute and percentage changes in pulmonary function before and after carbon-ion radiotherapy
Association between changes in pulmonary function and factors including the occurrence of adverse events and dosimetric parameters
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
NO
NO
1
Prevention
| Maneuver |
Pulmonary function tests at approximately 3, 6, and 12 months after carbon-ion radiotherapy
| 18 | years-old | <= |
| 100 | years-old | >= |
Male and Female
1. Patients scheduled to undergo carbon-ion radiotherapy for primary lung cancer or metastatic lung tumors between the date of institutional approval and December 31, 2029, OR patients who have provided consent for the existing study at our institution (N25-013: A prospective observational study evaluating changes in pulmonary function following carbon-ion radiotherapy for lung tumors), provided they are capable of giving written informed consent for this study.
2. Patients aged 18 years or older at the time of informed consent (regardless of gender).
3. Patients who are scheduled to visit our institution for follow-up for at least 1 year after the completion of treatment.
4. Patients judged by an investigator or attending physician to be capable of understanding the informed consent document.
Patients judged by an investigator or attending physician to be ineligible for this study
250
| 1st name | Ryo |
| Middle name | |
| Last name | Karita |
National Institutes for Quantum Science and Technology QST hospital
Section of Head, Neck and Thoracic Tumors, Department of Treatment and Diagnosis
263-8555
4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba
043-206-3306
karita.ryo@qst.go.jp
| 1st name | Ryo |
| Middle name | |
| Last name | Karita |
National Institutes for Quantum Science and Technology QST hospital
Section of Head, Neck and Thoracic Tumors, Department of Treatment and Diagnosis
263-8555
4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba
043-206-3306
karita.ryo@qst.go.jp
National Institutes for Quantum Science and Technology QST hospital
National Institutes for Quantum Science and Technology QST hospital
Other
National Institutes for Quantum Science and Technology Institutional Review Board
4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba
043-382-3703
helsinki@qst.go.jp
NO
国立研究開発法人量子科学技術研究開発機構QST病院
| 2026 | Year | 04 | Month | 27 | Day |
Unpublished
Preinitiation
| 2026 | Year | 03 | Month | 18 | Day |
| 2026 | Year | 04 | Month | 27 | Day |
| 2026 | Year | 05 | Month | 04 | Day |
| 2030 | Year | 12 | Month | 31 | Day |
| 2030 | Year | 12 | Month | 31 | Day |
| 2031 | Year | 06 | Month | 30 | Day |
| 2026 | Year | 04 | Month | 27 | Day |
| 2026 | Year | 04 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000070237